Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease

Respiratory Research

Volumn 14, Issue 1, 2013, Pages

  Ferrari, Renata ^a   Tanni, Suzana E ^a   Caram, Laura M O ^a   Corrêa, Corina ^a   Corrêa, Camila R ^a   Godoy, Irma ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Biomarkers; Chronic Obstructive Pulmonary Disease; Exercise; Inflammation

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PREDICTION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; WALKING; BLOOD; BRAZIL; EXERCISE TEST; MIDDLE AGED; PREVALENCE; RISK FACTOR; STATISTICS; SURVIVAL; SURVIVAL RATE;

BIOLOGICAL MARKERS; BRAZIL; C-REACTIVE PROTEIN; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84873948021     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-14-24     Document Type: Article

References (35)

1. Global Initiative for Chronic Obstructive Lung Disease guideline Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2010) Global Initiative for Chronic Obstructive Lung Disease, website. http://www.goldcopd.com/. Accessed June 15 2012, Global Initiative for Chronic Obstructive Lung Disease guideline.
2. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580. 10.1136/thx.2003.019588, 1747070, 15223864.
3. Tanni SE, Pelegrino NR, Angeleli AY, Correa C, Godoy I. Smoking and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. J Inflamm (Lond) 2010, 7:29.
4. Broekhuizen R, Wouters EFM, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2007, 61:17-22.
5. Garrod R, Marshall J, Barley E, Fredericks S, Hagan G. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease. Prim Care Respir J 2007, 16:236-240. 10.3132/pcrj.2007.00047, 17665081.
6. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174:867-874. 10.1164/rccm.200604-506OC, 16799074.
7. Kishimoto T. The biology of interleukin-6. Blood 1989, 1989(74):1-10.
8. Kolsum U, Roy K, Starkey C, Borrill Z, Truman N, Vestbo J, Singh D. The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. Int J Chron Obstruct Pulmon Dis J 2009, 4:149-156.
9. Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL, Shale DJ. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:1414-1418. 10.1164/ajrccm.164.8.2008109, 11704588.
10. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR. C- reactive protein in patients with COPD, control smokers, and non-smokers. Thorax 2006, 61:23-28. 2080714, 16143583.
11. Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK, Coxson HO, Bakke P, Mayer RJ, Celli B. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012, 7:e37483. 10.1371/journal.pone.0037483, 3356313, 22624038.
12. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, Lomas DA, Duvoix A, MacNee W, Rennard S, Silverman E, Vestbo J, Wouters E, Agustí A. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1065-1072. 10.1164/rccm.201110-1792OC, 22427534.
13. Pinto-Plata V, Casanova C, Mullerova H, de Torres JP, Corado H, Varo N, Cordova E, Zeineldine S, Paz H, Baz R, Divo M, Cortopassi F, Celli BR. Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. Respir Res 2012, 13:71. 10.1186/1465-9921-13-71, 3493287, 22906131.
14. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011, 163:53-67. 10.1111/j.1476-5381.2011.01218.x, 3085868, 21232047.
15. Jardim JR, Oliveira JA, Nascimento O. II Consenso Brasileiro de DPOC. J Bras Pneumol 2004, 30(Suppl 5):1-42.
16. American Thoracic Society statement Standardization of spirometry - Update. Am Rev Respir Dis 1987, 136:1285-1298. American Thoracic Society statement.
17. American Thoracic Society statement Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117. American Thoracic Society statement.
18. Kovelis D, Segretti NO, Probst VS, Lareau SC, Brunetto AF, Pitta F. Validação do Modified Pulmonary Functional Status and Dyspnea Questionnaire e da escala do Medical Research Council para o uso em pacientes com doença pulmonar obstrutiva crônica no Brasil. J Bras Pneumol 2008, 34:1008-1018. 10.1590/S1806-37132008001200005, 19180335.
19. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012. 10.1056/NEJMoa021322, 14999112.
20. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a Combined Comorbidity Index. J Clin Epidemiol 1994, 47:1245-1251. 10.1016/0895-4356(94)90129-5, 7722560.
21. R Development Core Team R: a language and environment for statistical computing 2011, Vienna, Austria: R Foundation for Statistical Computing, R Development Core Team.
22. Ferrari R, Tanni SE, Faganello MM, Caram LM, Lucheta PA, Godoy I. Three-year follow-up study of respiratory and systemic manifestations of chronic obstructive pulmonary disease. Braz J Med Biol Res 2011, 44:46-52. 10.1590/S0100-879X2010007500150, 21180880.
23. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 2012, 33:571-577. 10.1016/j.it.2012.07.003, 22883707.
24. Mehrotra N, Freire AX, Bauer DC, Harris TB, Newman AB, Kritchevsky SB, Meibohm B. Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score. Ann Epidemiol 2010, 20:223-232. 10.1016/j.annepidem.2009.11.005, 2827353, 20159492.
25. Waschki B, Kirsten A, Holz O, Müller KC, Meyer T, Watz H, Magnussen H. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011, 140:331-342. 10.1378/chest.10-2521, 21273294.
26. de Torres JP, Pinto-Plata V, Casanova C, Mullerova H, Córdoba-Lanús E, Muros de Fuentes M, Aguirre-Jaime A, Celli BR. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008, 133:1336-1343. 10.1378/chest.07-2433, 18339787.
27. Man SFP, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006, 61:849-853. 10.1136/thx.2006.059808, 2104755, 16738034.
28. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:250-255. 10.1164/rccm.200605-713OC, 17053205.
29. Sin DD, Man SF. Interleukin-6: a red herring or a real catch in COPD?. Chest 2008, 133:4-6. 10.1378/chest.07-2085, 18187736.
30. Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF, Lipinska I, O'Connor GT, Benjamin EJ. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008, 133:19-25. 10.1378/chest.07-0058, 17908709.
31. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005, 23:1-21. 10.1146/annurev.immunol.23.021704.115806, 15771564.
32. Nishida H, Horio T, Suzuki Y, Iwashima Y, Tokudome T, Fumiki Yoshihara F, Nakamura S, Kawano Y. Interleukin-6 as an independent predictor of future cardiovascular events in high-risk Japanese patients: Comparison with C-reactive protein. Cytokine 2011, 53:342-346. 10.1016/j.cyto.2010.12.005, 21190868.
33. Jenny NS, French B, Arnold AM, Strotmeyer ES, Cushman M, Chaves PH, Ding J, Fried LP, Kritchevsky SB, Rifkin DE, Sarnak MJ, Newman AB. Long-term assessment of inflammation and healthy aging in late life: The Cardiovascular Health Study All Stars. Gerontol A Biol Sci Med Sci 2012, 2012(67):970-976.
34. Brinkley TE, Leng X, Miller ME, Kitzman DW, Pahor M, Berry MJ, Marsh AP, Kritchevsky SB, Nicklas BJ. Chronic inflammation is associated with low physical function in older adults across multiple comorbidities. J Gerontol A Biol Sci Med Sci 2009, 64:455-461. 2657165, 19196644.
35. Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M, Simonsick EM, Satterfield S, Harris T, Kritchevsky SB. Inflammatory markers are associated with ventilator limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006, 61:10-16. 2080698, 16284220.